DRUG Stock Summary and Trading Ideas (Bright Minds Biosciences | NASDAQ:DRUG)

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences trades on the NASDAQ stock market under the symbol DRUG.

As of April 16, 2026, DRUG stock price declined to $88.65 with 196,869 million shares trading.

DRUG has a beta of 0.55, meaning it tends to be less sensitive to market movements. DRUG has a correlation of 0.01 to the broad based SPY ETF.

DRUG has a market cap of $867.63 million. This is considered a Small Cap stock.

In the last 3 years, DRUG traded as high as $123.75 and as low as $.93.

The top ETF exchange traded funds that DRUG belongs to (by Net Assets): IWM, IWO, VTWO, VFMO, IWC.

DRUG has outperformed the market in the last year with a price return of +173.5% while the SPY ETF gained +31.9%. However, in the short term, DRUG had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.4% vs +1.6% return in SPY. But in the last 2 weeks, DRUG shares have fared better than the market returning +23.6% compared to SPY +7.1%.

DRUG support price is $85.58 and resistance is $93.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRUG shares will trade within this expected range on the day.